- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03557242
Strategies to Prevent Transcatheter Heart Valve Dysfunction in Low Risk Transcatheter Aortic Valve Replacement
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This study aims to examine the optimal anticoagulation/antiplatelet regimen in low risk patients undergoing TAVR. The prospective randomized controlled arm of this study will assess the utility of short-term oral anticoagulation with warfarin compared to antiplatelet therapy alone after TAVR in low risk patients to reduce the incidence of structural valve deterioration manifest as clinical events, increased aortic valve gradients or transvalvular regurgitation, or subclinical leaflet thrombosis. Low risk subjects with symptomatic severe aortic stenosis will be enrolled to undergo TAVR. Following TAVR, subjects will be randomized to receive warfarin plus low dose Aspirin or low dose Aspirin monotherapy for 30-45 days. Subjects with other indications for anticoagulation (e.g. AF, DVT or PE) will not be randomized and instead will be followed in a separate registry arm. Baseline demographic, clinical, non-invasive imaging (echocardiography and CT), TAVR procedural details, clinical follow up data will be prospectively collected for all subjects. Echocardiography and contrast-enhanced 4D cardiac CT will be performed in all subjects between 30-45 days after TAVR to evaluate for evidence of structural valve deterioration.
This multicenter prospective randomized study will enroll 200 consecutive low risk subjects with symptomatic severe aortic stenosis into the treatment arms of the study. Up to 100 additional subjects with a pre-existing indication for anticoagulation (e.g. atrial fibrillation, deep venous thrombosis or pulmonary embolism) or who are not eligible for randomization after TAVR due to development of a new indication for anticoagulation will be enrolled into the registry arm of the study.
Inclusion of this registry arm will ensure that the secondary objective pooled analysis of patient level data from this study and the Low Risk TAVR (LRT) study, truly represents an all-comers cohort of low risk patients undergoing TAVR, and does not exclude a significant subgroup.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
California
-
San Diego, California, United States, 92121
- Foundation for Cardiovascular Medicine
-
-
District of Columbia
-
Washington, District of Columbia, United States, 20010
- Washington Hospital Center
-
-
New Jersey
-
Ridgewood, New Jersey, United States, 07450
- The Valley Hospital
-
-
New York
-
Stony Brook, New York, United States, 11794
- Stony Brook Hospital
-
-
Oklahoma
-
Tulsa, Oklahoma, United States, 74104
- St. John Health System
-
-
Virginia
-
Norfolk, Virginia, United States, 23507
- Sentara Norfolk General Hospital
-
Richmond, Virginia, United States, 23229
- Henrico Doctors' Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- ADULT
- OLDER_ADULT
- CHILD
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Severe, degenerative AS, defined as:
- Mean aortic valve gradient ≥40 mm Hg OR Vmax ≥4 m/sec AND
- Calculated aortic valve area ≤1.0 cm2 OR aortic valve area index ≤0.6 cm2/m2
- Symptomatic AS, defined as a history of at least one of the following:
- Dyspnea that qualifies at New York Heart Association (NYHA) class II or greater
- Angina pectoris
- Cardiac syncope
- The Heart Team agrees that the patient is low-risk, quantified by an estimated risk of death ≤3% by the calculated STS score for operative mortality at 30 days; AND agrees that SAVR would be an appropriate therapy if offered
- A surgeon who is experienced in Surgical Aortic Valve Replacement (SAVR) has spoken with the patient in person and stipulates that the patient understands his/her alternatives for FDA approved therapy, including open heart surgery to replace their aortic valve
- The institutional Heart Team determines that transfemoral TAVR is appropriate
- Aortic valve anatomy and dimensions suitable for TAVR using a commercially available valve
- Iliofemoral artery anatomy and dimensions suitable for transfemoral TAVR using a commercially available valve and delivery system
- Procedure status is elective
- Expected survival is at least 24 months
Exclusion Criteria:
- Subject unable or unwilling to give informed consent
- Concomitant disease of another heart valve or the aorta that requires either transcatheter or surgical intervention
- Any condition that is considered a contraindication for placement of a bioprosthetic aortic valve (e.g. patient requires a mechanical aortic valve)
- Aortic stenosis secondary to a bicuspid aortic valve
- Prior bioprosthetic surgical aortic valve replacement
- Mechanical heart valve in another position
- End-stage renal disease requiring hemodialysis or peritoneal dialysis, or a creatinine clearance <20 cc/min
- Left ventricular ejection fraction <20%
- Recent (<6 months) history of stroke
- Symptomatic carotid or vertebral artery disease, or recent (<6 weeks) surgical or endovascular treatment of carotid stenosis
- Any contraindication to oral antiplatelet or anticoagulation therapy following the procedure, including recent or ongoing bleeding, or HASBLED score >3 (Table 2 - HASBLED scoring system)
- Severe coronary artery disease that is unrevascularized
- Recent (<30 days) acute myocardial infarction
- Patient cannot undergo transfemoral TAVR for anatomic reasons (as determined by supplemental imaging studies); this would include inadequate size of iliofemoral access vessels or an aortic annulus size that is not accommodated by the commercially available valves
- Any comorbidity not captured by the STS score that would make SAVR high risk, as determined by a cardiothoracic surgeon who is a member of the heart team; this includes:
- Porcelain or severely atherosclerotic aorta
- Frailty
- Hostile chest
- Internal mammary artery or other conduit either crosses midline of sternum or is adherent to sternum
- Severe pulmonary hypertension (PA systolic pressure > 2/3 of systemic pressure)
- Severe right ventricular dysfunction
- Ongoing sepsis or infective endocarditis
- Severe chronic obstructive pulmonary disease, as demonstrated by forced expiratory volume (FEV1) <750 cc
- Liver failure with Childs class C or D
- Pre-procedure shock, inotropes, mechanical assist device, or cardiac arrest
- Pregnancy or intent to become pregnant prior to completion of all protocol follow-up procedures
- Known allergy to warfarin or aspirin
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
OTHER: Warfarin plus Aspirin
100 subjects will be randomized electronically through the Electronic Data Capture System in a 1:1 fashion to warfarin plus low dose aspirin for 30-45 days
|
Transcatheter Aortic Valve Replacement
Subjects randomized to this arm will receive Warfarin plus aspirin for 30- 45 days post TAVR
|
OTHER: Aspirin Monotherapy
100 subjects will be randomized electronically through the Electronic Data Capture System in a 1:1 fashion to low dose aspirin monotherapy for 30-45 days
|
Transcatheter Aortic Valve Replacement
Subjects randomized to this arm will receive aspirin only post TAVR
|
OTHER: Registry Arm
Upto an additional 100 subjects with preexisting indication for anti coagulation (e.g.
atrial fibrillation, deep venous thrombosis, pulmonary embolism) or who are not eligible for randomization after TAVR due to development of a new indication for anti coagulation will be enrolled in the registry arm of the study.
|
Transcatheter Aortic Valve Replacement
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
All Cause Mortality
Time Frame: 30 days
|
30 days
|
|
All Stroke
Time Frame: 30 days
|
disabling and non-disabling, ischemic, hemorrhagic
|
30 days
|
Life-threatening and Major Bleeding
Time Frame: 30 days
|
30 days
|
|
Major Vascular Complications
Time Frame: 30 Days
|
30 Days
|
|
Hospitalizations for valve-related symptoms or worsening congestive heart failure
Time Frame: 30 days
|
30 days
|
|
Hypoattenuated leaflet thickening (HALT)
Time Frame: 30 days
|
30 days
|
|
At least moderately restricted leaflet motion (RELM)
Time Frame: 30 days
|
30 days
|
|
Hemodynamic dysfunction
Time Frame: 30 Days
|
(mean aortic valve gradient ≥20 mm Hg, AND/OR EOA ≤1.0 cm2 AND/OR DVI<0.
35, AND/OR moderate or severe prosthetic valve regurgitation)
|
30 Days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
All-cause mortality
Time Frame: 1 year
|
1 year
|
|
Acute kidney injury
Time Frame: 1 year
|
1 year
|
|
VARC-2 device success:
Time Frame: 1 year
|
|
1 year
|
All stroke
Time Frame: 1 year
|
(disabling and non-disabling, ischemic and hemorrhagic)
|
1 year
|
Life-threatening and major bleeding
Time Frame: 1 year
|
1 year
|
|
Major vascular complications
Time Frame: 1 year
|
1 year
|
|
Hospitalizations for valve-related symptoms or worsening congestive heart failure
Time Frame: 1 year
|
1 year
|
|
Pacemaker implantation
Time Frame: 1 year
|
1 year
|
|
Endocarditis
Time Frame: 1 year
|
1 year
|
Collaborators and Investigators
Investigators
- Principal Investigator: Ron S Waksman, MD, MedStar Cardiovascular Research Network
Publications and helpful links
General Publications
- Medranda GA, Soria Jimenez CE, Torguson R, Case BC, Forrestal BJ, Ali SW, Shea C, Zhang C, Wang JC, Gordon P, Ehsan A, Wilson SR, Levitt R, Parikh P, Bilfinger T, Hanna N, Buchbinder M, Asch FM, Weissman G, Shults CC, Garcia-Garcia HM, Ben-Dor I, Satler LF, Waksman R, Rogers T. Lifetime management of patients with symptomatic severe aortic stenosis: a computed tomography simulation study. EuroIntervention. 2022 Aug 5;18(5):e407-e416. doi: 10.4244/EIJ-D-21-01091.
- Rogers T, Shults C, Torguson R, Shea C, Parikh P, Bilfinger T, Cocke T, Brizzio ME, Levitt R, Hahn C, Hanna N, Comas G, Mahoney P, Newton J, Buchbinder M, Moreno R, Zhang C, Craig P, Asch FM, Weissman G, Garcia-Garcia HM, Ben-Dor I, Satler LF, Waksman R. Randomized Trial of Aspirin Versus Warfarin After Transcatheter Aortic Valve Replacement in Low-Risk Patients. Circ Cardiovasc Interv. 2021 Jan;14(1):e009983. doi: 10.1161/CIRCINTERVENTIONS.120.009983. Epub 2021 Jan 11.
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Heart Diseases
- Cardiovascular Diseases
- Aortic Valve Disease
- Heart Valve Diseases
- Ventricular Outflow Obstruction
- Aortic Valve Stenosis
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Peripheral Nervous System Agents
- Enzyme Inhibitors
- Analgesics
- Sensory System Agents
- Anti-Inflammatory Agents, Non-Steroidal
- Analgesics, Non-Narcotic
- Anti-Inflammatory Agents
- Antirheumatic Agents
- Fibrinolytic Agents
- Fibrin Modulating Agents
- Platelet Aggregation Inhibitors
- Cyclooxygenase Inhibitors
- Antipyretics
- Anticoagulants
- Aspirin
- Warfarin
Other Study ID Numbers
- LRT 2.0
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Aortic Stenosis
-
Hospices Civils de LyonRecruiting
-
Abbott Medical DevicesActive, not recruitingSevere Aortic Stenosis | Symptomatic Degenerative Aortic StenosisSpain, Italy, United Kingdom, Germany, Switzerland, Czechia, Australia, Belgium, Poland
-
Edwards LifesciencesActive, not recruitingAortic Stenosis | Aortic Regurgitation | Symptomatic Aortic StenosisChina
-
Anteris Technologies Ltd.Active, not recruitingAortic Valve Calcification | Severe Aortic Valve Stenosis | Symptomatic Aortic StenosisGeorgia
-
Anteris Technologies Ltd.Active, not recruitingAortic Stenosis | Aortic Valve Calcification | Severe Aortic Valve Stenosis | Symptomatic Aortic StenosisUnited States
-
Edwards LifesciencesCompletedAortic Stenosis | Aortic Regurgitation | Symptomatic Aortic StenosisChina
-
Ningbo Jenscare Biotechnology Co., Ltd.UnknownAortic Regurgitation | Severe Aortic Stenosis
-
Genesis Medtech CorporationRecruitingDiseases of Aortic Valve | Aortic Stenosis DiseaseChina
-
Pan XiangbinRecruiting
-
Colibri Heart Valve LLCRecruiting
Clinical Trials on TAVR
-
Niguarda HospitalRecruitingAortic Valve Stenosis | Transcatheter Aortic Valve ReplacementItaly
-
Abbott Medical DevicesCompletedAortic Valve StenosisGermany, Netherlands, Italy, Switzerland, Denmark
-
Edwards LifesciencesActive, not recruitingSymptomatic Severe Aortic StenosisUnited States
-
IRCCS Policlinico S. DonatoCompletedFailed Transcather Aortic ValveItaly
-
University of UlmCompletedPM Implantation After TAVRGermany
-
Michele De BonisCompletedAortic StenosisDenmark, Hungary, Italy
-
Edwards LifesciencesAmerican College of CardiologyCompletedCalcific Aortic Stenosis | Severe | SymptomaticUnited States
-
IRCCS Policlinico S. DonatoNot yet recruiting
-
Duk-Woo Park, MDCardioVascular Research Foundation, KoreaRecruitingHeart Valve Diseases | Aortic Valve InsufficiencyKorea, Republic of, United States, China
-
IHF GmbH - Institut für HerzinfarktforschungYale University; Boston Scientific GroupActive, not recruiting